You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Diagnoses and procedures in incident GnRH agonist users, comparing those with and without a diagnosis of prostate cancer in the SEER tumor registries

From: Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

Diagnoses and procedures in incident GnRH agonist usersa
  SEER groupb Non-SEER groupc  
  n % nd % p-valuee
Procedures related to diagnosis and histologic confirmation of prostate cancer a      
Hospitalization 3691 21.2 338 19.9 0.75
Transurethral resection of prostate 1504 8.7 56 3.3 0.08
Prostate Biopsy 13728 79.0 1153 67.8 0.01
Transrectal Ultrasound 10342 59.5 868 51.1 0.11
Radical Prostatectomy 766 4.4 51 3.0 0.47
Any of the above 15122 87.0 1204 70.8 <0.01
Other treatment/work-up a      
Radiation Therapy 3156 18.2 85 5.0 <0.01
CT scan/MRI pelvis 6421 36.9 503 29.6 0.16
Bone Scan 11048 63.6 910 53.5 0.06
  1. aWithin 3 months before or after diagnosis of prostate cancer (date based on Medicare claims)
  2. bDiagnosis of prostate cancer registered in SEER
  3. cDiagnosis of prostate cancer from Medicare claims, but not in SEER and excluding men who may have had a delay in reporting, moved out of the SEER area at the time of diagnosis or failed the SEER to Medicare linkage
  4. dSample sizes inflated by a factor of 20 to account for 5% sample and rounded to nearest integer
  5. eChi-square test for comparison of proportions between SEER and non-SEER group, based on uninflated sample sizes
  6. GnRH; Gonadotropin-releasing hormone
  7. SEER; Surveillance, Epidemiology and End-Results